Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...

The Japanese chemical company has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a ...

Bain said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare industry.

Bain Capital, an investment firm that has spread its life sciences bets mainly across companies developing novel new medicines, is acquiring Mitsubishi Tanabe Pharma Corporation in a multi-billion ...

The deal values Mitsubishi Tanabe Pharma at about ¥510 billion ($3.3 billion), according to a statement on Friday. The transaction is expected to be completed in the third quarter, pending ...

TOKYO (Reuters) -U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), saying it was encouraged by prospects of regulatory change ...

Bain Capital is making its latest biotech bid in Japan, where it plans to acquire Mitsubishi Tanabe Pharma Corp. The Boston-based private investment firm is buying Tanabe Pharma from Mitsubishi ...

A deal could value Mitsubishi Tanabe Pharma at more than ¥500 billion yen ($3.3 billion), the people said. Bain has emerged as the likeliest buyer for the Japanese pharmaceutical company after ...

Bain Capital has agreed to acquire Tanabe Pharma, the pharma arm of Mitsubishi Chemical Group Corporation. The deal puts Tanabe Pharma at a valuation of about $3.3 billion. Founded in 1678, Tanabe ...

The U.S. investment company said Friday that it will buy Mitsubishi Tanabe Pharma for about 510 billion yen, equivalent to $3.37 billion.

TOKYO, Feb 7 (Reuters) - U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), saying it was encouraged by prospects of ...